2021 Q2 Form 10-Q Financial Statement

#000159075021000070 Filed on August 12, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2
Revenue $1.090M $168.0K
YoY Change 548.81% -93.32%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.523M $2.710M
YoY Change 140.7% -5.24%
% of Gross Profit
Research & Development $12.57M $3.836M
YoY Change 227.55% -55.39%
% of Gross Profit
Depreciation & Amortization $25.00K $64.00K
YoY Change -60.94% -36.0%
% of Gross Profit
Operating Expenses $19.09M $6.542M
YoY Change 191.78% -42.89%
Operating Profit -$18.00M -$6.374M
YoY Change 182.37% -28.72%
Interest Expense $34.00K -$60.00K
YoY Change -156.67% -220.0%
% of Operating Profit
Other Income/Expense, Net $34.00K $33.00K
YoY Change 3.03% -88.0%
Pretax Income -$17.96M -$6.440M
YoY Change 178.94% -27.64%
Income Tax
% Of Pretax Income
Net Earnings -$17.96M -$6.435M
YoY Change 179.16% -27.66%
Net Earnings / Revenue -1648.07% -3830.36%
Basic Earnings Per Share -$2.21 -$1.82
Diluted Earnings Per Share -$2.21 -$1.82
COMMON SHARES
Basic Shares Outstanding 8.107M shares 3.538M shares
Diluted Shares Outstanding 8.107M shares 3.538M shares

Balance Sheet

Concept 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $109.3M $30.60M
YoY Change 257.19% -30.3%
Cash & Equivalents $27.70M $30.58M
Short-Term Investments $81.60M $0.00
Other Short-Term Assets $4.110M $1.700M
YoY Change 141.76% -55.26%
Inventory
Prepaid Expenses
Receivables $2.051M $248.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $115.5M $32.52M
YoY Change 255.04% -32.36%
LONG-TERM ASSETS
Property, Plant & Equipment $298.0K $379.0K
YoY Change -21.37% -41.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $97.00K $1.000K
YoY Change 9600.0% -98.0%
Total Long-Term Assets $2.740M $964.0K
YoY Change 184.23% 37.32%
TOTAL ASSETS
Total Short-Term Assets $115.5M $32.52M
Total Long-Term Assets $2.740M $964.0K
Total Assets $118.2M $33.49M
YoY Change 253.0% -31.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.392M $286.0K
YoY Change 736.36% -76.79%
Accrued Expenses $14.15M $3.020M
YoY Change 368.54% -23.47%
Deferred Revenue $288.0K
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.400M
YoY Change -15.0%
Total Short-Term Liabilities $16.83M $6.723M
YoY Change 150.33% -26.51%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $5.400M
YoY Change -100.0% -12.9%
Other Long-Term Liabilities $1.167M $211.0K
YoY Change 453.08%
Total Long-Term Liabilities $1.167M $211.0K
YoY Change 453.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.83M $6.723M
Total Long-Term Liabilities $1.167M $211.0K
Total Liabilities $19.29M $12.31M
YoY Change 56.65% -19.75%
SHAREHOLDERS EQUITY
Retained Earnings -$315.3M -$182.7M
YoY Change 72.58% 24.44%
Common Stock $86.00K $531.0K
YoY Change -83.8% 71.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.91M $21.17M
YoY Change
Total Liabilities & Shareholders Equity $118.2M $33.49M
YoY Change 253.0% -31.36%

Cashflow Statement

Concept 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$17.96M -$6.435M
YoY Change 179.16% -27.66%
Depreciation, Depletion And Amortization $25.00K $64.00K
YoY Change -60.94% -36.0%
Cash From Operating Activities -$14.63M -$6.790M
YoY Change 115.46% -5.3%
INVESTING ACTIVITIES
Capital Expenditures -$49.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$11.15M $0.00
YoY Change -100.0%
Cash From Investing Activities -$11.20M $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 7.051M 1.260M
YoY Change 459.6% -3250.0%
NET CHANGE
Cash From Operating Activities -14.63M -6.790M
Cash From Investing Activities -11.20M 0.000
Cash From Financing Activities 7.051M 1.260M
Net Change In Cash -18.78M -5.530M
YoY Change 239.64% -195.02%
FREE CASH FLOW
Cash From Operating Activities -$14.63M -$6.790M
Capital Expenditures -$49.00K $0.00
Free Cash Flow -$14.58M -$6.790M
YoY Change 114.74% -4.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001590750
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Registrant Name
EntityRegistrantName
Viridian Therapeutics, Inc./DE
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
CY2019 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate201602Member
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
CY2021Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36483
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1187261
dei Entity Address Address Line1
EntityAddressAddressLine1
203 Crescent Street, Bldg. 17, Suite 102B
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02453
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
272-4600
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
VRDN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9587155 shares
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27704000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45897000 USD
CY2021Q2 us-gaap Short Term Investments
ShortTermInvestments
81597000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
81742000 USD
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4110000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1972000 USD
CY2021Q2 mgen Unbilled Contracts Receivable Related Party Current
UnbilledContractsReceivableRelatedPartyCurrent
2051000 USD
CY2020Q4 mgen Unbilled Contracts Receivable Related Party Current
UnbilledContractsReceivableRelatedPartyCurrent
0 USD
CY2021Q2 us-gaap Assets Current
AssetsCurrent
115462000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
129611000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
298000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
309000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1567000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
478000 USD
CY2021Q2 mgen Other Assets Related Party Noncurrent
OtherAssetsRelatedPartyNoncurrent
778000 USD
CY2020Q4 mgen Other Assets Related Party Noncurrent
OtherAssetsRelatedPartyNoncurrent
856000 USD
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
97000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1000 USD
CY2021Q2 us-gaap Assets
Assets
118202000 USD
CY2020Q4 us-gaap Assets
Assets
131255000 USD
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2392000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
670000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14150000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000 USD
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
288000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
301000 USD
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16830000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10674000 USD
CY2021Q2 mgen Other Liabilities Related Party Noncurrent
OtherLiabilitiesRelatedPartyNoncurrent
1293000 USD
CY2020Q4 mgen Other Liabilities Related Party Noncurrent
OtherLiabilitiesRelatedPartyNoncurrent
501000 USD
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1167000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43000 USD
CY2021Q2 us-gaap Liabilities
Liabilities
19290000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
11218000 USD
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8608886 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8608886 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4231135 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4231135 shares
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
86000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
42000 USD
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
259786000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
218089000 USD
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-8000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315311000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278887000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
98912000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
120037000 USD
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118202000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
131255000 USD
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1090000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
168000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2541000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
996000 USD
CY2021Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12565000 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3836000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
26371000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
9939000 USD
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6523000 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2706000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12683000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5429000 USD
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
19088000 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
6542000 USD
us-gaap Operating Expenses
OperatingExpenses
39054000 USD
us-gaap Operating Expenses
OperatingExpenses
15368000 USD
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17998000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6374000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-36513000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-14372000 USD
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
34000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
89000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
128000 USD
CY2021Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
0 USD
CY2020Q2 us-gaap Interest And Debt Expense
InterestAndDebtExpense
94000 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
0 USD
us-gaap Interest And Debt Expense
InterestAndDebtExpense
235000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17964000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6435000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36424000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14479000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
9000 USD
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-4000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
0 USD
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17955000 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6435000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36428000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14479000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17964000 USD
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-17964000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6435000 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6435000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-36424000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-36424000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14479000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-14479000 USD
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.82
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.41
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.41
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3285123 shares
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8106765 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8106765 shares
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3538490 shares
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3538490 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7226447 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7226447 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3285123 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
120037000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2021Q1 mgen Stock Issued During Period Value Warrants Exercised Value
StockIssuedDuringPeriodValueWarrantsExercisedValue
940000 USD
CY2021Q1 mgen Stock Issued During Period Value Issued For Exercise Of Stock Options And Vesting Of Restricted Stock Units
StockIssuedDuringPeriodValueIssuedForExerciseOfStockOptionsAndVestingOfRestrictedStockUnits
307000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
12000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3175000 USD
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-13000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-18460000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
105998000 USD
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3817000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
15754000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13000 USD
mgen Non Cash Lease Expense
NonCashLeaseExpense
131000 USD
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
9000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-17964000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
98912000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
16000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
664000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-8044000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
27000000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
623000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-6435000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
21171000 USD
us-gaap Net Income Loss
NetIncomeLoss
-36424000 USD
us-gaap Net Income Loss
NetIncomeLoss
-14479000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
6992000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1287000 USD
mgen Non Cash Lease Expense
NonCashLeaseExpense
-1200000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-67000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-481000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-281000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2156000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-622000 USD
mgen Increase Decrease In Unbilled Revenue Related Party
IncreaseDecreaseInUnbilledRevenueRelatedParty
2051000 USD
mgen Increase Decrease In Unbilled Revenue Related Party
IncreaseDecreaseInUnbilledRevenueRelatedParty
0 USD
mgen Increase Decrease In Contract With Customer Related Party Liability
IncreaseDecreaseInContractWithCustomerRelatedPartyLiability
779000 USD
mgen Increase Decrease In Contract With Customer Related Party Liability
IncreaseDecreaseInContractWithCustomerRelatedPartyLiability
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1601000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-810000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5683000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2412000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26170000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
69000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15248000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
67381000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
67042000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2000000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
75000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-333000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2001000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8529000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
19783000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
218000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1193000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1333000 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
1726000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8311000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18983000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18192000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5736000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45897000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24846000 USD
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27704000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30582000 USD
us-gaap Interest Paid Net
InterestPaidNet
0 USD
us-gaap Interest Paid Net
InterestPaidNet
145000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
120000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0 USD
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
19000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-4000 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
0 USD
mgen Amortization Of Stock Issuance Costs
AmortizationOfStockIssuanceCosts
30000 USD
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-315300000 USD
CY2021Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
109300000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution.</span></div>
CY2020Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q2 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2021Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
9000.0 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-4000.0 USD
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2020Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2020Q2 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 USD
us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0 USD
CY2020Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
CY2021Q2 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2048000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3752000 USD
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1750000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3443000 USD
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
298000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
309000 USD
CY2021Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
142000 USD
CY2021Q2 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
75000 USD
CY2021Q2 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
67000 USD
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
25000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
58000 USD
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
132000 USD
CY2021Q2 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
10314000 USD
CY2020Q4 mgen Accrued Outsourcing Clinicaland Preclinical Studies
AccruedOutsourcingClinicalandPreclinicalStudies
5400000 USD
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2566000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1963000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
455000 USD
CY2021Q2 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
88000 USD
CY2020Q4 mgen Accrued Legal Fees Current
AccruedLegalFeesCurrent
380000 USD
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
278000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
796000 USD
CY2021Q2 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2020Q4 mgen Accrued Liabilityof Warrantson Temporary Equity
AccruedLiabilityofWarrantsonTemporaryEquity
100000 USD
CY2021Q2 mgen Accrued License Agreement Liability
AccruedLicenseAgreementLiability
177000 USD
CY2020Q4 mgen Accrued License Agreement Liability
AccruedLicenseAgreementLiability
86000 USD
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
215000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
523000 USD
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14150000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9703000 USD
mgen Lessee Operating Lease Number Of Renewal Terms
LesseeOperatingLeaseNumberOfRenewalTerms
2 renewal_term
CY2021Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P3Y
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1600000 USD
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1600000 USD
CY2020Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.06
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P12M
CY2021Q2 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P9M
CY2021Q2 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
100000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
700000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
700000 USD
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.06
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1800000 USD
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
412000 USD
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1200000 USD
CY2021Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
200000 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
100000 USD
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
200000 USD
CY2021Q2 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
34000 USD
mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
68000 USD
CY2020Q2 mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
100000 USD
mgen Operating Leases Operating Expense
OperatingLeasesOperatingExpense
200000 USD
CY2021Q1 mgen Capital Stock Shares Authorized
CapitalStockSharesAuthorized
205000000 shares
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 mgen Common Stock Voteper Share
CommonStockVoteperShare
1 vote
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q2 mgen Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
441545 shares
CY2020Q4 mgen Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet
498500 shares
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.94
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
498500 shares
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
16.00
mgen Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
56955 shares
mgen Class Of Warrant Or Right Exercised In Period Weighted Average Grant Date Fair Value
ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue
16.50
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
441545 shares
CY2021Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.94
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2703614 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2291207 shares
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3817000 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
623000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6992000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1287000 USD
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
36800000 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y5M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25827559 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
846320 shares

Files In Submission

Name View Source Status
0001590750-21-000070-index-headers.html Edgar Link pending
0001590750-21-000070-index.html Edgar Link pending
0001590750-21-000070.txt Edgar Link pending
0001590750-21-000070-xbrl.zip Edgar Link pending
a2021063010qex101.htm Edgar Link pending
a2021063010qex104.htm Edgar Link pending
a2021063010qex311.htm Edgar Link pending
a2021063010qex312.htm Edgar Link pending
a2021063010qex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
mgen-20210630.htm Edgar Link pending
mgen-20210630.xsd Edgar Link pending
mgen-20210630_cal.xml Edgar Link unprocessable
mgen-20210630_def.xml Edgar Link unprocessable
mgen-20210630_htm.xml Edgar Link completed
mgen-20210630_lab.xml Edgar Link unprocessable
mgen-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending